This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Asia: Oligonucleotide & Peptide Therapeutics
24-26 Feb, 2026
Grand Nikko Tokyo DaibaTokyo

Husam Younis, PhD
Senior Vice President, Development Science at Avidity Biosciences
Speaker

Profile

Husam Younis serves as the Senior Vice President of Development Sciences and Global Program Head of the DMD franchise at Avidity Biosciences. He has over 20 years experience in the pharmaceutical/biotechnology industry with focus in research and development. His experience spans multiple drug modalities and therapeutic areas, including rare disease, and has led research and development teams to advance multiple programs from preclinical research to first-in-human, proof -of-concept and pivotal clinical studies. Currently he serves as Global Program Head for del zota (DMD44). He also leads the toxicology, PKPD and biomarker sciences functions at Avidity Biosciences. Prior to Avidity Biosciences, he held positions in leadership roles at NGM Biopharmaceuticals (South San Francisco, CA), Ionis Pharmaceuticals (Carlsbad, CA) and Pfizer Inc (San Diego, CA) in nonclinical development and translational medicine. Graduate training in pharmacology and toxicology and pharmacy practice obtained at College of Pharmacy, University of Arizona.

Agenda Sessions

  • Advancing RNA Therapeutics: Preclinical Translation of Antibody Oligonucleotide Conjugates (AOC)

    2:15pm